Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.

Marta BellesiniMatteo BianchinChiara CorradiMarco Paolo DonadiniEmanuel RaschiAlessandro Squizzato

Published in: Clinical drug investigation (2020)

DOACs and DAAs are under-investigated for DDI risk. Real-world studies are needed to assess the clinical relevance of the pharmacokinetic interactions with dabigatran and describe the actual spectrum of possible DDIs between DAAs and other DOACs.

Keyphrases

direct oral anticoagulants
atrial fibrillation
venous thromboembolism
atomic force microscopy
case control
emergency department
adverse drug